DK2691371T3 - Benzoesyresalt af otamixaban - Google Patents

Benzoesyresalt af otamixaban

Info

Publication number
DK2691371T3
DK2691371T3 DK12711858.6T DK12711858T DK2691371T3 DK 2691371 T3 DK2691371 T3 DK 2691371T3 DK 12711858 T DK12711858 T DK 12711858T DK 2691371 T3 DK2691371 T3 DK 2691371T3
Authority
DK
Denmark
Prior art keywords
otamixaban
benzoic acid
acid salt
salt
benzoic
Prior art date
Application number
DK12711858.6T
Other languages
Danish (da)
English (en)
Inventor
Norbert Nagel
Bruno Baumgartner
Harald Berchtold
Timothy Ayers
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2691371T3 publication Critical patent/DK2691371T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK12711858.6T 2011-03-29 2012-03-27 Benzoesyresalt af otamixaban DK2691371T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305348 2011-03-29
US201161500342P 2011-06-23 2011-06-23
PCT/EP2012/055364 WO2012130821A1 (en) 2011-03-29 2012-03-27 Benzoic acid salt of otamixaban

Publications (1)

Publication Number Publication Date
DK2691371T3 true DK2691371T3 (da) 2015-06-22

Family

ID=44065390

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12711858.6T DK2691371T3 (da) 2011-03-29 2012-03-27 Benzoesyresalt af otamixaban

Country Status (21)

Country Link
US (1) US8993602B2 (enExample)
EP (1) EP2691371B1 (enExample)
JP (1) JP5959617B2 (enExample)
KR (1) KR101852226B1 (enExample)
CN (1) CN103562183B (enExample)
AU (1) AU2012234325B2 (enExample)
BR (1) BR112013025105A2 (enExample)
CA (1) CA2830965C (enExample)
CY (1) CY1116659T1 (enExample)
DK (1) DK2691371T3 (enExample)
ES (1) ES2539236T3 (enExample)
HR (1) HRP20150613T1 (enExample)
IL (1) IL228574A (enExample)
MX (1) MX2013011266A (enExample)
MY (1) MY161396A (enExample)
PL (1) PL2691371T3 (enExample)
PT (1) PT2691371E (enExample)
RU (1) RU2597423C2 (enExample)
SG (1) SG193612A1 (enExample)
SI (1) SI2691371T1 (enExample)
WO (1) WO2012130821A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193932A1 (en) 2011-03-29 2013-11-29 Sanofi Sa Otamixaban formulations with improved stability
CN106565698B (zh) * 2016-08-15 2019-03-08 南京帕隆材料科技有限公司 取代噻唑类衍生物及其制备方法和用途
CN106518859B (zh) * 2016-08-15 2019-01-18 南京帕隆材料科技有限公司 噻唑类衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
IL125163A0 (en) * 1996-01-02 1999-01-26 Rhone Poulenc Rorer Pharma Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법
BR112012001900A2 (pt) * 2009-07-29 2016-03-15 Sanofi Sa otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st

Also Published As

Publication number Publication date
SG193612A1 (en) 2013-11-29
PT2691371E (pt) 2015-07-20
US20140024684A1 (en) 2014-01-23
KR101852226B1 (ko) 2018-04-25
ES2539236T3 (es) 2015-06-29
MX2013011266A (es) 2014-03-27
MY161396A (en) 2017-04-14
EP2691371B1 (en) 2015-03-18
CN103562183A (zh) 2014-02-05
RU2013148005A (ru) 2015-05-10
HRP20150613T1 (hr) 2015-07-17
IL228574A (en) 2015-07-30
BR112013025105A2 (pt) 2017-06-06
JP5959617B2 (ja) 2016-08-02
KR20140022851A (ko) 2014-02-25
CA2830965A1 (en) 2012-10-04
SI2691371T1 (sl) 2015-07-31
HK1189584A1 (en) 2014-06-13
AU2012234325A1 (en) 2013-10-17
AU2012234325B2 (en) 2016-08-11
CN103562183B (zh) 2015-12-23
WO2012130821A1 (en) 2012-10-04
CA2830965C (en) 2019-04-09
CY1116659T1 (el) 2017-03-15
PL2691371T3 (pl) 2015-08-31
IL228574A0 (en) 2013-12-31
EP2691371A1 (en) 2014-02-05
US8993602B2 (en) 2015-03-31
JP2014509622A (ja) 2014-04-21
RU2597423C2 (ru) 2016-09-10

Similar Documents

Publication Publication Date Title
NL301241I2 (nl) Belantamab mafodotin
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
DK2685832T3 (da) Stabiliserede hypohalogensyreopløsninger
DK2863918T3 (da) Saltkrystaller af en pde1- inhibitor
IL229513A0 (en) Imidazopyridine compounds
EP2850067A4 (en) Carboxylic acid compounds
DK3235812T3 (da) Deutererede derivater af ivacaftor
HUE036301T2 (hu) Kinolin vegyület
DK3336097T3 (da) Fremstilling af ikke-krystallinsk obeticholsyre
HRP20180809T1 (hr) Inhibicijski spojevi metaloenzima
DK3050972T3 (da) Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
DK2771364T3 (da) Fremstilling af heterodimere proteiner
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
CO6910197A2 (es) Compuestos novedosos
BR112014012016A2 (pt) compostos
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
LTC3246325I2 (lt) 2-acilaminotiazolo junginio kristalai
SMT201600071B (it) Derivato di acido pirrolidina-3-ilacetico
LT3202769T (lt) Fosfaplatinos junginių gryninimo būdas
EP2770998A4 (en) Factor ixa inhibitors
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
SMT201600353B (it) Sali di acido solfonico di imidazoli eterociclilammide-sostituiti
EP2755663A4 (en) MicroRNA Inhibitors
IL228574A0 (en) Benzoic acid salt of otamixban
ITVI20110301A1 (it) Struttura di sale